TargImmune Therapeutics develops targeted apoptosis and immune modulators (TAIMs) using a modular, synthetic nucleic acid delivery platform that employs nanoparticles to deliver therapeutics directly to cancer cells. This technology addresses the limitations of existing nucleic acid therapies by selectively destroying cancer cells and enhancing treatment efficacy across various oncology applications.
Funding
$49.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing nucleic acid therapies face challenges in selectively targeting cancer cells and achieving sufficient efficacy across diverse oncology applications. Traditional methods often lack precision, leading to off-target effects and limited therapeutic impact.
Solution
TargImmune Therapeutics is developing Targeted Apoptosis and Immune Modulators (TAIMs), a novel class of oncology compounds, using a modular, synthetic nucleic acid delivery platform. This platform employs nanoparticles to deliver interchangeable nucleic acid therapeutics directly to cancer cells, overcoming the limitations of existing nucleic acid therapies. By mimicking natural viral infection and antiviral defense responses, the technology selectively destroys cancer cells. The platform acts as a vehicle to enhance treatment efficacy and unlock new treatment frontiers across multiple therapy areas.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more effective and targeted cancer therapies.
Features
- Modular, synthetic nucleic acid delivery platform for targeted drug delivery
- Nanoparticle-based delivery system for enhanced precision
- Targeted Apoptosis and Immune Modulators (TAIMs) for selective cancer cell destruction
- Mimics natural viral infection and antiviral defense responses
- Interchangeable nucleic acid therapeutics for versatile applications